These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10314517)

  • 1. Revised physician labelling for neuroleptic drugs: Food and Drug Administration. Notice.
    Fed Regist; 1980 Aug; 45(155):52931-3. PubMed ID: 10314517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice.
    Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic-induced hyperprolactinemia.
    Bostwick JR; Guthrie SK; Ellingrod VL
    Pharmacotherapy; 2009 Jan; 29(1):64-73. PubMed ID: 19113797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-the-counter human drugs; labeling requirements. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(51):13254-303. PubMed ID: 10557606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA "black box" labeling.
    Meyer RJ
    Ann Emerg Med; 2003 Apr; 41(4):559-60. PubMed ID: 12658256
    [No Abstract]   [Full Text] [Related]  

  • 6. PDA response. FDA advance notice of proposed rulemaking on electronic identification/signatures. Parenteral Drug Association.
    J Parenter Sci Technol; 1993; 47(1):4-8. PubMed ID: 8445499
    [No Abstract]   [Full Text] [Related]  

  • 7. Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products.
    Hexsel CL; Bangert SD; Hebert AA; Lim HW
    J Am Acad Dermatol; 2008 Aug; 59(2):316-23. PubMed ID: 18485529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of drugs for unlabeled indications.
    Nightingale SL
    Am Fam Physician; 1986 Sep; 34(3):269. PubMed ID: 3751849
    [No Abstract]   [Full Text] [Related]  

  • 9. OTC labeling reform.
    J Am Pharm Assoc (Wash); 1997; NS37(6):619-20. PubMed ID: 9425787
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA extra-label restriction on drugs.
    Varney JE
    J Am Vet Med Assoc; 1983 Dec; 183(12):1372, 1374-5. PubMed ID: 6654717
    [No Abstract]   [Full Text] [Related]  

  • 11. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of antipsychotic agents in the management of behavioral disorders in the elderly with dementia: evaluating recent clinical data.
    Worz CR
    Director; 2008; 16(2):17-20. PubMed ID: 19343879
    [No Abstract]   [Full Text] [Related]  

  • 13. "Safer, but not safe enough".
    Crombie HD
    Conn Med; 2006; 70(10):645. PubMed ID: 17190395
    [No Abstract]   [Full Text] [Related]  

  • 14. ASHP statement on the use of medications for unlabeled uses.
    Am J Hosp Pharm; 1992 Aug; 49(8):2006-8. PubMed ID: 1442846
    [No Abstract]   [Full Text] [Related]  

  • 15. Educating patients about their medications: the potential and limitations of written drug information.
    Shrank WH; Avorn J
    Health Aff (Millwood); 2007; 26(3):731-40. PubMed ID: 17485751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stoning a dead bird: advertising limits on approved new drugs.
    Strobos J
    Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
    [No Abstract]   [Full Text] [Related]  

  • 18. Pediatric priorities: legislative and regulatory initiatives to expand research on the use of medicines in pediatric patients.
    Labson MS
    J Health Care Law Policy; 2002; 6(1):34-72. PubMed ID: 15017951
    [No Abstract]   [Full Text] [Related]  

  • 19. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 20. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.